3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Burkitt Lymphoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia
3
Recurrence
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Biphenotypic, Acute
1
Interventions
Rituximab
44
Cyclophosphamide
38
Prednisone
26
Doxorubicin
25
Vincristine
20
Magnetic Resonance Spectroscopy
20
Lenalidomide
19
Specimen Handling
18
Gemcitabine
18
Biopsy
15
polatuzumab vedotin
14
Oxaliplatin
14
glofitamab
12
obinutuzumab
11
ibrutinib
10
Etoposide
10
CT-P10
9
fludarabine
8
Dexamethasone
8
prednylidene
7
pembrolizumab
7
deltacortene
7
Prednisolone
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
7
venetoclax
6
tafasitamab
6
acalabrutinib
6
fludarabine phosphate
5
R-CHOP protocol
5
Immunotherapy, Adoptive
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
Inotuzumab Ozogamicin
×
90 days
×
Clear all
NCT01679119
2026-04-07
INCA
University College, London
Phase 2
Completed
129 enrolled
7 charts